Compass Pathways Submits COMP360 Psilocybin Application for Treatment-Resistant Depression
Key Clinical Summary
- Compass Pathways announced November 9, 2026, that it completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for investigational COMP360 psilocybin for treatment-resistant depression (TRD).
- The application is supported by two phase 3 trials and a phase 2b study involving more than 1000 participants with chronic TRD, all of which met their primary endpoints, according to the manufacturer.
- COMP360 remains investigational and is not FDA-approved; Compass Pathways anticipates a potential US launch in the first half of 2027, contingent on regulatory approval.
Compass Pathways has completed submission of an NDA to the FDA for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression (TRD), the company announced November 9, 2026. The submission follows a clinical development program involving participants across three studies.
Data Supporting the Application
According to Compass, the NDA is supported by findings from two phase 3 clinical trials and a phase 2b study evaluating COMP360 in patients with chronic TRD. The company reported that all three studies, which enrolled more than 1000 participants with chronic TRD, met their respective primary endpoints.
According to estimates cited by the company, approximately 4 million people in the United States have TRD, and fewer than 5% currently receive a treatment specifically indicated for the condition.
Compass also cited a national survey of individuals with TRD and their caregivers examining the condition's impact on daily functioning and family life. Among surveyed patients, 95% described themselves as struggling to function or manage daily life, while approximately 70% of caregivers reported negative effects on their family's social, physical, or mental health.
Clinical Implications
The NDA submission represents a regulatory development for investigational psilocybin treatment in TRD, although it does not establish FDA approval or clinical availability. For clinicians treating patients with TRD, the regulatory review will determine whether COMP360 can become an approved treatment option. The company expects a potential US launch in the first half of 2027, subject to approval.
The application also highlights the growing focus on psychedelic agents for psychiatric treatment following recent federal efforts to accelerate their clinical development and regulatory review.
